Genetic variant linked to narcolepsy risk, according to study
29 Sep 2008

A genetic variant has been linked to a higher risk of the sleep disorder narcolepsy by Japanese scientists.

Published in the journal Nature Genetics and carried out by staff from the University of Tokyo, the study examined the genetic code of several hundred volunteers, some of who had narcolepsy and others who did not.

The variant they found was linked to a 79 per cent higher risk of narcolepsy in Japanese people, with a 40 per cent increased chance in other ethnic groups.

"It is found close to two genes, CPT1B and CHKB, which have already been singled out as candidates for involvement in the disorder - as they both have a role in regulating sleep," the BBC reports.

The researcher said they think the results of their study could help physicians to understand the underlying mechanisms responsible for the sleep disorder, especially what causes the shortage in the neuropeptide hormone hypocretin, which many scientists believe is the cause of narcolepsy.

Login and visit the Insomnia Knowledge Centre

Print Article    Bookmark

• Prenatal smoking warning against infant development 01/12/08
• Lack of sleep may be linked with heart disease risk, says study 11/11/08
• New insomnia research looks at neurochemical abnormalities 03/11/08
• Study links respiratory patterns to insomnia in breast cancer patients 27/10/08
• Cognitive behaviour therapy helpful for cancer survivors suffering insomnia, study suggests 02/10/08

• ZIMOVANE - 49.42%
  Short-term treatment of insomnia. Transient, situational or chronic insomnia and insomnia secondary to psychiatric disorders where it is debilitating or severe ...
  
  
• Zopiclone (Generic) - 49.42%
  Short-term treatment of insomnia. Transient, situational or chronic insomnia and insomnia secondary to psychiatric disorders where it is debilitating or severe ...
  
  
• MOGADON Tablets - 47.95%
  Short-term treatment of insomnia when it is severe, disabling or subjecting the individual to unacceptable distress, where daytime sedation is acceptable. An underlying cause for insomnia should be sought before deciding upon the use of benzodiazepines for symptomatic relief. Benzodiazepines are not ...
  
  
• DALMANE Capsules - 47.95%
  Short-term treatment of insomnia when it is severe, disabling or subjecting the individual to extreme distress. Dalmane is helpful in overcoming difficulties in getting to sleep and also in the problem of frequent nocturnal awakenings. Its properties make it particularly indicated where the total ...
  
  
• CIRCADIN Prolonged-release Tablets - 46.1%
  Circadin is indicated as monotherapy for the short-term treatment of primary insomnia characterised by poor quality of sleep in patients who are aged 55 or over ...
  
  
• VALIUM (anxiety) - 46.1%
  Orally, short-term treatment of anxiety that is severe or disabling occurring alone or with insomnia. Acute alcohol withdrawal. Night terrors and somnambulism in children. By injection, severe acute anxiety, muscle spasm ...